[Event Report] Special Diet Member Study Session “Examining Prospects for International Collaboration on Antimicrobial Resistance (AMR) Ahead of the G7 Hiroshima Summit” (February 28, 2023)
date : 4/19/2023
Tags: AMR, Diet Member Briefing
Health and Global Policy Institute (HGPI) and the Global Leaders Group on Antimicrobial Resistance, which was established by the World Health Organization (WHO) and its partners, co-hosted a study session for members of the Diet entitled “Examining Prospects for International Collaboration on Antimicrobial Resistance (AMR) Ahead of the G7 Hiroshima Summit”
The study session featured a lecture from Dame Sally Davies, who has led global discussions on AMR for many years and previously served as Chief Medical Officer for England. The lecture covered a number of topics including the impact of AMR on the global economy, the importance of antimicrobial innovation, and One Health.
The lecture was followed by a lively opinion exchange session with many questions from attending Diet members.
■ Purpose
Antimicrobial resistance, or AMR, is a global menace that, according to an estimate published in a British medical journal in 2022, was the direct cause of 1.27 million deaths in 2019. AMR has been called a “silent pandemic” and “The next threat after COVID-19.” Given the lack of progress in the development of new antimicrobials, it has become necessary for us to discuss the need for global collaboration among G7 members and in the international community.
Key points of the lecture
- Antimicrobials are not only vital tools for treating infectious diseases including HIV and malaria, they are also essential for treating cancer and for safely performing various surgical procedures. However, existing antimicrobials have been growing less effective due to the emergence of new AMR bacteria and the propagation of AMR infections. It has been predicted that AMR will result in fewer treatment options within five years, even in the field of cancer. If antimicrobials become ineffective, it may lead to losses of life from dental procedures and cesarean sections.
- AMR control is also important within the frameworks of national and economic security. The manufacturing bases for the active pharmaceutical ingredients (APIs) of 40 key antimicrobials are concentrated in India and China. It has also been projected that failure to take measures to combat AMR now might cost the global economy up to $100 trillion by 2050 and cause a major reduction in GDP.
- The antimicrobial market is collapsing. We must reestablish an environment that enables new antimicrobials to be launched continuously. New classes of antimicrobials have not reached real-world clinical settings and patients since the late 1980s. In addition, the number of newly approved antimicrobials in Japan has declined by half over the past three decades. Japan has not established a mechanism for bringing antimicrobials to market.
- Countries like Japan and the U.K. have started introducing pull incentives to restructure the antimicrobial market and support innovation. Japan’s proposed FY2023 budget allocates 1.1 billion yen for pull incentives and discussions on an Antimicrobial Drug Securement Project are now advancing. To rebuild a climate in which new antimicrobials can be launched in a continuous manner, the antimicrobial market must be improved by restructuring it in a manner that makes the antimicrobial business more predictable and that allows antimicrobials manufacturers to be able to count on generating certain amounts of revenue.
- Antimicrobials are public goods, which means we must improve the structure of the antimicrobial market through measures based on global collaboration, including the introduction of pull incentives, as well as by implementing measures for AMR control based on the One Health approach. As the President of the G7 Hiroshima Summit in 2023, expectations are high for leadership from Japan when advancing measures to combat AMR.
[Program] (interpretation was provided for all items, title omitted)
Opening remarks
Yasuhisa Shiozaki (Member of the Global Leaders Group on Antimicrobial Resistance / Former Minister of Health, Labor and Welfare)
Greetings
Keizo Takemi (Member, House of Councillors / Japanese Co-Chairman, UK-Japan 21st Century Group)
Yoshitake Yokokura (Honorary President, Japan Medical Association)
Isao Kurauchi (President, Japan Veterinary Medical Association)
Lecture “Prospects for International Partnership on AMR issues in the G7 Countries”
Dame Sally Davies (Former Chief Medical Advisor to the UK Government / UK Government Special Envoy on Antimicrobial Resistance / Member of the Global Leaders Group on Antimicrobial Resistance)
Question and answer session
日本語
Top Research & Recommendations Posts
- [Announcement] A Turning Point Towards Building Green Healthcare Systems (June 5, 2024)
- [Policy Recommendations] Developing a National Health and Climate Strategy for Japan (June 26, 2024)
- [Publication Report] Guidance on Patient and Public Involvement (PPI) in Health Policymaking: Necessary Initiatives and Good Examples from the Public and Government (March 31, 2024)
- [Policy Recommendations] Obesity Control Promotion Project 2023 “The Next Steps for Engaging and Cooperating with Patients, Citizens, and Communities for Implements of Obesity Control Measurements” (April 8, 2024)
- [Research Report] Healthcare DX Project Research Report of Interviews ”Expectations for the Coming Era of Healthcare DX from People Living with Health Concerns” (June 10, 2024)
- [Policy Recommendations] Recommendation for the Basic Policy on Economic and Fiscal Management and Reform 2024 (June 11, 2024)
- [Policy Recommendations] Kidney Disease Control Promotion Project 2023 “Establishing Kidney Disease Control Measures with Patient, Citizen, and Community Engagement and Collaboration” Policy Recommendations, a Collection of Good Practices of Chronic Kidney Disease (CKD) and Control Measures in Local Governments (February 14, 2024)
- [Research Report] Building a Mental Health Program for Children and Measuring its Effectiveness (June 16, 2022)
- [Public Comment Submission] Web based consultations on NCDs and mental health by World Health Organization (June 25, 2024)
- [Research Report] The 2023 Public Opinion Survey on Satisfaction in Healthcare in Japan and Healthcare Applications of Generative AI (January 11, 2024)
Featured Posts
-
2024-06-21
[Event Report] HGPI Special Seminar – HGPI Celebrates its 20th Anniversary: Reflecting on HGPI’s Journey from the Past to the Future (January 16, 2024)
-
2024-06-25
[Public Comment Submission] Web based consultations on NCDs and mental health by World Health Organization (June 25, 2024)
-
2024-06-26
[Event Report] Global Expert Meeting “Innovation in Cancer Care in Developing Countries ~City Cancer Challenge Initiatives“ (June 20, 2024)
-
2024-06-26
[Registration Open] (Webinar) The 127th HGPI Seminar: Current Issues and Future Prospects in Establishing a Health System and Protecting Public Health Through Policy (July 18, 2024)
-
2024-07-01
[Registration Open] Meaningful Involvement Promotion Project Online Expert Meeting “Shaping the Future of Health Policy with People with Lived Experience and Citizens” (July 26, 2024)